| Literature DB >> 29892223 |
Xue-Yin Pan1,2,3, Yang Yang1,2,3, Hong-Wu Meng1,2,3, Hai-di Li1,2,3, Xin Chen1,2,3, Hui-Min Huang1,2,3, Fang-Tian Bu1,2,3, Hai-Xia Yu1,2,3, Qin Wang1,2,3, Cheng Huang1,2,3, Xiao-Ming Meng1,2,3, Jun Li1,2,3.
Abstract
The activation of hepatic stellate cells (HSCs) is a central event in the progression of liver fibrosis. Multiple studies proved that DNA methylation might accelerate HSCs activation. However, the specific pathogenesis of liver fibrosis remains not fully addressed. Our laboratory performed Genome methylation screening to find out the methylated gene in mice with liver fibrosis. The pilot experiments showed that the promoter of prostacyclin synthase (PTGIS) gene was hypermethylated in CCl4-induced liver fibrosis mouse model. Moreover, the down-regulated PTGIS expression can be restored by DNMTs-RNAi and 5-aza-2-deoxycytidine (5-azadC), an inhibitor of DNA methyltransferase (DNMTs). Methylation-specific PCR (MSP) showed that the methylation status of PTGIS in HSC-T6 cells cultures with TGF-β1 (10 ng/mL) was elevated compared with control group. Chromatin immunoprecipitation (ChIP) assay indicated that PTGIS methylation was mainly induced by DNMT1 and DNMT3b. We further investigated the function of PTGIS in liver fibrosis by Recombinant Hepatic-adeno-associated virus (rAAV8)-PTGIS overexpression. The data indicated that overexpression of PTGIS in mouse liver accompanied by elevated apoptosis-related proteins expression in primary HSCs. Conversely, PTGIS silencing mediated by RNAi enhanced the expression of α-SMA and COL1a1 in vitro. Those results illustrated that adding PTGIS expression inhibits the activation of HSCs and alleviates liver fibrosis. Therefore, our study unveils the role of PTGIS in HSCs activation, which may provide a possible explanation for CCl4-mediated liver fibrosis.Entities:
Keywords: DNA methylation; PTGIS; apoptosis; gene expression; hepatic stellate cells; proliferation
Year: 2018 PMID: 29892223 PMCID: PMC5985735 DOI: 10.3389/fphar.2018.00553
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The preparation methods of solution used in primary HSCs isolation
| (1) PB solution | |
| PBC solution | 40 mL |
| ddH2O | Up to 1 L |
| (2) PBC solution | |
| NaCl | 103.75 g |
| KCl | 6.25 g |
| Hepes | 28.7 g |
| 1M NaOH solution | 75 mL |
| ddH2O | Up to 500 mL |
The solution preparation method of PBC: dissolve NaCl (103.75 g), KCl (6.25 g) and Hepes (28.70 g) in H2O (350 mL) while stirring. When all has been dissolvedadd 1M NaOH (75 mL). Add H2O to a total volume of 500 mL. | |
| (3) 1% BSA solution | |
| BSA | 1 g |
| PB solution | Up to 100 mL |
| (4) Digestion buffer | |
| type IV collagenase | 35 mg |
| Pronase | 35 mg |
| 1M CaCl2 solution | 1 mL |
| PBC solution | 99 mL |
| (5) Nycodenz solution | |
| Nycodenz | 28.7 g |
| GBSS solution | Up to 100 mL |
| (6) GBSS solution | |
| KCl | 0.37 g |
| CaCl2 | 0.225 g |
| MgCl2.6H2O | 0.21 g |
| MgSO4 | 0.0342 g |
| KH2PO4 | 0.03 g |
| NaHCO3 | 2.27 g |
| NaH2PO4 | 0.1196 g |
| Glucose | 1.0 g |
| ddH2O | Up to 1000 mL |
Primers used in RT-qPCR.
| Gene | Forward Primer (5′ → 3′) | Reverse Primer (5′ → 3′) |
|---|---|---|
| Mouse | ||
| PTGIS | TCCTCAAGAATCCGGAAGCC | TCTTCTGTGGGAGTGTGGTC |
| Colla1 | TGTAAACTCCCTCCACCCCA | TCGTCTGTTTCCAGGGTTGG |
| α-SMA | CGGGCTTTGCTGGTGATG | CCCTCGATGGATGGGAAA |
| GAPDH | GGACCTCATGGCCTACATGG | TAGGGCC TCTCTTGCTCAGT |
| Rat | ||
| PTGIS | TTATTACTGTTGCTGCTGCT | ATCCTGGTAAGGAAGCTGGC |
| Colla1 | GATCCTGCCGATGTCGCTAT | TGTAGGCTACGCTGTTCTTGCA |
| α-SMA | CGAAGCGCAGAGCAAGAGA | CATGTCGTCCCAGTTGGTGAT |
| β-actin | CCCATCTATGAGGGTTACGC | TTTAATGTCACGCACGATTTC |
The siRNA sequences used in RNA interference analysis.
| Gene | Sense (5′ → 3′) | Antisense (5′ → 3′) |
|---|---|---|
| RAT | ||
| PTGIS | GCUCACGGAAGCCAUGUAUTT | AUACAUGGCUUCCGUGAGCTT |
| Negative control | UUCUCCGAACGUGUCACGUTT | ACGUGACACGUUCGGAGAATT |
| DNMT1 | CCCAGAGUAUGCACCAAUATT | UAUUGGUGCAUACUCUGGGTT |
| DNMT3a | GCGUCACACAGAAGCAUAUTT | AUAUGCUUCUGUGUGACGCTT |
| DNMT3b | AGAUGACAGGUGCCCAGAGUU | CUCUGGGCACCUGUCAUGUUU |
| Negative control | UUCUCCGAACGUGUCACGUTT | ACGUGACACGUUCGGAGAATT |
The characteristics of antibodies.
| Protein | Application | Origin | Dilution |
|---|---|---|---|
| PTGIS | WB &IHC&IF | sc-20933, Santa Cruz, CA, United States | 1:200 &1:50&1:50 |
| COL1a1 | WB | bs10423R, Bioss, China | 1:300 |
| α-SMA | WB &IHC&IF | bs0189R, Bioss, China | 1:300 &1:200&1:50 |
| DNMT1 | WB | ab13537, Abcam, United Kingdom | 1:800 |
| DNMT3a | WB | ab13888, Abcam, United Kingdom | 1:800 |
| DNMT3b | WB | ab2851, Abcam, United Kingdom | 1:800 |
| C-myc | WB | D3N8F, Cell Signaling Technology, United States | 1:800 |
| CyclinD1 | WB | 92G2, Cell Signaling Technology, United States | 1:800 |
| Bax | WB | 2772s, Cell Signaling Technology, United States | 1:800 |
| Bcl-2 | WB | ab194583, Cell Signaling Technology, United States | 1:800 |
| Casepase3 | WB | 9662, Cell Signaling Technology, United States | 1:800 |